635318-55-7|Pomaglumetad methionil free base|(1R,4S,5S,6S)-4-((S)-2-amino-4-(methylthio)butanamido)-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid 2,2-dioxide|-范德生物科技公司

Pomaglumetad methionil free base

NMR下载 COA and HPLC MSDS下载
names：
(1R,4S,5S,6S)-4-((S)-2-amino-4-(methylthio)butanamido)-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid 2,2-dioxide
CAS号：
635318-55-7
MDL Number：
MF(分子式)： C12H18N2O7S2 MW(分子量)： 366.403
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	(1R,4S,5S,6S)-4-((S)-2-amino-4-(methylthio)butanamido)-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid 2,2-dioxide
英文别名	LY2140023; LY-2140023; LY 2140023; LY2140023 monohydrate; Prodrug of LY-404039; Pomaglumetad methionil
CAS号	635318-55-7
SMILES	O=C([C@]1(NC([C@@H](N)CCSC)=O)CS([C@@]2([H])[C@H](C(O)=O)[C@@]12[H])(=O)=O)O
Inchi	InChI=1S/C12H18N2O7S2/c1-22-3-2-5(13)9(15)14-12(11(18)19)4-23(20,21)8-6(7(8)12)10(16)17/h5-8H,2-4,13H2,1H3,(H,14,15)(H,16,17)(H,18,19)/t5-,6+,7+,8-,12-/m0/s1
InchiKey	VOYCNOJFAJAILW-CAMHOICYSA-N
分子式 Formula	C12H18N2O7S2
分子量 Molecular Weight	366.403
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Pomaglumetad methionil free base(CAS:635318-55-7 ):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Pomaglumetad methionil, also known as LY2140023, is a prodrug of LY-404039 and a a novel metabotropic glutamate 2/3 receptor agonist peptide prodrug. Pomaglumetad methionil is currently in clinical development as a potential new treatment for schizophrenia. LY2140023 is generally well tolerated and appears to have a low association with adverse events related to dopamine D2 receptor antagonism and with weight gain, which are commonly seen with current antipsychotics.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Su P, Lu JY, Seeman P, Liu F. Glutamate drug reduces dopamine inhibition of phosphorylation. Synapse. 2016 Feb;70(2):45-8. doi: 10.1002/syn.21874. Epub 2015 Dec 2. PubMed PMID: 26583745.

[2]Marek GJ. When is a Proof-of-Concept (POC) not a POC? Pomaglumetad (LY2140023) as a Case Study for Antipsychotic Efficacy. Curr Pharm Des. 2015;21(26):3788-96. PubMed PMID: 26044978.

[3] Kinon BJ, Millen BA, Zhang L, McKinzie DL. Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia. Biol Psychiatry. 2015 Dec 1;78(11):754-62. doi: 10.1016/j.biopsych.2015.03.016. Epub 2015 Mar 19. PubMed PMID: 25890643.

[4] Zhang W, Mitchell MI, Knadler MP, Long A, Witcher J, Walling D, Annes W, Ayan-Oshodi M. Effect of pomaglumetad methionil on the QT interval in subjects with schizophrenia. Int J Clin Pharmacol Ther. 2015 Jun;53(6):462-70. doi: 10.5414/CP202289. PubMed PMID: 25881753.

[5] Moulton RD, Ruterbories KJ, Bedwell DW, Mohutsky MA. In vitro characterization of the bioconversion of pomaglumetad methionil, a novel metabotropic glutamate 2/3 receptor agonist peptide prodrug. Drug Metab Dispos. 2015 May;43(5):756-61. doi: 10.1124/dmd.114.062893. Epub 2015 Mar 9. PubMed PMID: 25755052.

6: Deutschenbaur L, Beck J, Kiyhankhadiv A, Mühlhauser M, Borgwardt S, Walter M, Hasler G, Sollberger D, Lang UE. Role of calcium, glutamate and NMDA in major depression and therapeutic application. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;6

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开